Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer

MLA

Ferry A.L.M. Eskens, et al. “Phase I Study of the Selective BRAFV600 Inhibitor Encorafenib (LGX818) Combined with Cetuximab and with or without the α-Specific PI3K Inhibitor BYL719 in Patients with Advanced BRAF-Mutant Colorectal Cancer.” Journal of Clinical Oncology, vol. 32, May 2014, p. 3514. EBSCOhost, https://doi.org/10.1200/jco.2014.32.15_suppl.3514.

APA

Ferry A.L.M. Eskens, Yasuhide Yamada, Jason E. Faris, Takayuki Yoshino, Jean-Pierre Delord, Robin M.J.M. van Geel, Martin Schuler, Peijuan Zhu, Elena Elez, René Bernards, Emin Avsar, Anna Spreafico, Johanna C. Bendell, Josep Tabernero, Tim Demuth, Zev A. Wainberg, Arkendu Chatterjee, Martijn P. Lolkema, Jan H.M. Schellens, & Petr Kavan. (2014). Phase I study of the selective BRAFV600 inhibitor encorafenib (LGX818) combined with cetuximab and with or without the α-specific PI3K inhibitor BYL719 in patients with advanced BRAF-mutant colorectal cancer. Journal of Clinical Oncology, 32, 3514. https://doi.org/10.1200/jco.2014.32.15_suppl.3514

Chicago

Ferry A.L.M. Eskens, Yasuhide Yamada, Jason E. Faris, Takayuki Yoshino, Jean-Pierre Delord, Robin M.J.M. van Geel, Martin Schuler, et al. 2014. “Phase I Study of the Selective BRAFV600 Inhibitor Encorafenib (LGX818) Combined with Cetuximab and with or without the α-Specific PI3K Inhibitor BYL719 in Patients with Advanced BRAF-Mutant Colorectal Cancer.” Journal of Clinical Oncology 32 (May): 3514. doi:10.1200/jco.2014.32.15_suppl.3514.